NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
Hand-out
Press Releases
NTC Srl  
December 5, 2024

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

MILAN, Dec. 5, 2024 /PRNewswire/ -- NTC, an international R&D focused pharmaceutical company headquartered in Italy, presents positive results from Phase II MIRAKLE study, a multicentre, randomized, blinded-assessor, phase II

logo salamanca press

Salamanca Press

Local & Social